Renalytix Plc (RNLX) - News Archive

Renalytix plc Expands U.S. Presence with OTCQB Listing, Accelerating Developments in Kidney Disease ManagementRenalytix plc, a leader in the field of AI-driven diagnostics aimed at improving kidney health, announced the...

Renalytix plc, a renowned artificial intelligence-enabled in vitro diagnostics company, has joined forces with the Steno Diabetes Center (Steno) in Copenhagen, marking an unprecedented expansion of their KidneyIntelX pl...

Medicare Approves Coverage for KidneyIntelX.dkd: Significant Milestone for Chronic Kidney Disease ManagementIn a groundbreaking development aimed at revolutionizing chronic kidney disease (CKD) management, Medicare has...

In a major development, Renalytix plc, a leading medical technology firm redefining critical global diseases care, has announced a registered direct offering of ordinary shares. The offering, priced at $0.75 per NASDAQ...

Chronic Kidney Disease (CKD) affects millions of people worldwide and imposes a significant burden on healthcare systems globally. As we enter a new era of personalized medicine, risk prediction and tailored treatment p...

Chronic kidney disease (CKD) is a global public health crisis with millions of lives at stake. Patients facing this condition require innovative approaches to not only slow down disease progression but also effectively...